Rare diseases
Investigational molecules
Locations
359 conditions with trials, the busiest first
849 trials across Europe, recruiting first
A study testing SPY072 compared to placebo in adults with moderately to severely active rheumatologic disease
BulgariaA study to test if tibulizumab works and is safe for adults with systemic sclerosis
HungaryA study testing BFB759 compared to placebo to evaluate effectiveness and safety in adult patients with atopic dermatitis
BulgariaStudy of navenibart to prevent attacks in adults and adolescents with Hereditary Angioedema
AustriaComparison of zasocitinib and deucravacitinib in adults with moderate to severe plaque psoriasis
BulgariaStudy of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis
BulgariaStudy of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis
GermanyStudy of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis
AustriaStudy of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks
BelgiumLong-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa
BelgiumStudy of Ruxolitinib Cream for Children and Adolescents Ages 6-17 with Moderate Atopic Dermatitis Who Did Not Respond Well to Standard Treatments
BelgiumStudy on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis
BelgiumThe therapies tested most often in Skin and subcutaneous tissue disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
